Separate Parkinson from similar disorders
- Trial ID
- NCT06490926
- Official Title
- NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
- Goal
- Separate Parkinson from similar disorders
- Status
- RECRUITING
- Sponsor
- Fujian Medical University Union Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 180 participants
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
Plain-Language Summary
The goal is to find serum metabolic biomarkers that can reliably tell Parkinson's disease apart from atypical parkinsonian syndromes like multiple system atrophy and progressive supranuclear palsy, and to see whether subtypes such as MSA-P versus MSA-C or tremor-predominant versus PIGD Parkinson's have distinct metabolic fingerprints. The approach uses NMR spectroscopy on blood serum to measure many small-molecule metabolites, creating a noninvasive metabolic profile that could become a diagnostic fingerprint, and it is purely observational so it does not change your medications or interact with levodopa. Eligible participants are adults 45 to 80 years old with diagnoses of idiopathic Parkinson's disease, MSA, or PSP by standard criteria, while people with hereditary or secondary parkinsonism, prior deep brain stimulation, or a history of cancer are excluded.
Locations
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to find serum metabolic biomarkers that can reliably tell Parkinson's disease apart from atypical parkinsonian syndromes like multiple system atrophy and progressive supranuclear palsy, and to see whether subtypes such as MSA-P versus MSA-C or tremor-predominant versus PIGD Parkinson's have distinct metabolic fingerprints. The approach uses NMR spectroscopy on blood serum to measure many small-molecule metabolites, creating a noninvasive metabolic profile that could become a diagnostic fingerprint, and it is purely observational so it does not change your medications or interact with levodopa. Eligible participants are adults 45 to 80 years old with diagnoses of idiopathic Parkinson's disease, MSA, or PSP by standard criteria, while people with hereditary or secondary parkinsonism, prior deep brain stimulation, or a history of cancer are excluded.
- Who can participate?
- Participants must be between 45 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 5 months.